Welcome to our dedicated page for PLXP news (Ticker: PLXP), a resource for investors and traders seeking the latest updates and insights on PLXP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PLXP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PLXP's position in the market.
PLx Pharma Inc. (NASDAQ: PLXP) announced the upcoming availability of its FDA-approved VAZALORE liquid-filled aspirin capsules in over 4,500 Walmart stores nationwide by mid-August. The three SKUs include VAZALORE 81 mg (12 count), VAZALORE 81 mg (30 count), and VAZALORE 325 mg (30 count). Walmart has already started placing 'Coming Soon' shelf placeholders, enhancing customer visibility. VAZALORE aims to provide safer aspirin therapy, reducing the risk of stomach issues compared to traditional aspirin products.
PLx Pharma Inc. (NASDAQ: PLXP) announced virtual presentations at two healthcare conferences. The JMP Securities Life Sciences Conference will take place on June 16, 2021, at 12:30 PM ET, and the Raymond James Human Health Innovation Conference on June 21, 2021, at 2:40 PM ET. Key executives Natasha Giordano and Rita O’Connor will present the company’s innovative drug delivery platform, PLxGuard™, and its lead product, VAZALORE™, an FDA-approved liquid-filled aspirin capsule. Webcast links for both events are provided for public access.
PLx Pharma Inc. (NASDAQ: PLXP) announced FDA approval for its novel VAZALORE liquid-filled aspirin capsules (325 mg and 81 mg). The company secured $71.4 million in gross proceeds from a public offering to support the launch of VAZALORE, set for Q3 2021. In Q1 2021, PLx reported no revenue, a significant decrease from the previous year. Research and development expenses rose to $1.0 million, reflecting increased manufacturing for VAZALORE, while general and administrative expenses were slightly up at $2.6 million. The net loss was $11.9 million, or $0.73 per share, primarily due to a non-cash loss related to warrant liability.
PLx Pharma Inc. (NASDAQ: PLXP) will release its first quarter 2021 financial results on May 14, 2021, before U.S. markets open. The company will host a conference call at 8:30 a.m. ET, led by CEO Natasha Giordano and CFO Rita O'Connor, to discuss the results and provide business updates. VAZALORE, its lead product, is an FDA-approved liquid-filled aspirin capsule designed to offer fast and reliable platelet inhibition while minimizing stomach risks compared to traditional aspirin forms.
PLx Pharma Inc. (NASDAQ: PLXP) announced FDA approval of its supplemental new drug applications for VAZALORE 325 mg and 81 mg, the first liquid-filled aspirin capsules. The U.S. commercial launch is planned for Q3 2021, supported by a recent $63 million public offering. Financial results show a Q4 2020 net loss of $8.5 million, significantly up from $2.3 million in Q4 2019. For the full year, PLx reported a net loss of $16.9 million, down from $34.3 million in 2019. As of December 31, 2020, cash and equivalents stood at $22.4 million.
PLx Pharma Inc. (NASDAQ: PLXP) announced that its President and CEO, Natasha Giordano, along with CFO Rita O'Connor, will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 2:30 PM Eastern Time. The presentation will focus on their clinically-validated PLxGuard™ drug delivery platform and its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg, which offer effective aspirin therapy with reduced gastrointestinal risks. The event will be webcast live and archived for 30 days on the company's website.
PLx Pharma Inc. (NASDAQ: PLXP) plans to release its 2020 fourth quarter financial results on March 12, 2021, before market open. The Company will host a conference call on the same day at 8:30 a.m. ET to discuss the results and provide a business update. PLx Pharma is focused on its PLxGuard™ drug delivery platform, which enhances absorption and reduces gastrointestinal risks associated with traditional medications. VAZALORE, their FDA-approved liquid-filled aspirin capsule, demonstrates strong platelet inhibition and is designed for patients with vascular conditions and diabetes.
PLx Pharma Inc. (NASDAQ: PLXP) announced a public offering of 7,875,000 shares at $8.00 per share, aiming to raise approximately $63 million before expenses. The underwriters have a 30-day option to purchase an additional 1,181,250 shares. The offering is expected to close around March 5, 2021. The funds will be used for general corporate purposes, including working capital and capital expenditures. Raymond James & Associates and Oppenheimer & Co. Inc. are managing the offering, which is part of a previously filed shelf registration with the SEC.
PLx Pharma Inc. (NASDAQ: PLXP) has announced plans for an underwritten public offering of its common stock. The company may also offer underwriters a 30-day option to purchase an additional 15% of shares at the public offering price. Proceeds will be used for general corporate purposes, including working capital. The offering is subject to market conditions and follows an effective shelf registration statement filed with the SEC.
PLx Pharma Inc. has received FDA approval for its pioneering liquid-filled aspirin capsules, VAZALORE, in both 325 mg and 81 mg doses. This breakthrough product is aimed at patients requiring reliable antiplatelet therapy and offers fast, predictable platelet inhibition with reduced stomach erosion risks compared to traditional aspirin. The commercial launch is scheduled for Q3 2021, representing a significant step toward enhancing patient care in vascular medicine. PLx's PLxGuard delivery platform underpins this innovation, promising safer and more effective products.
